Phase 3 Gastro-oesophageal Reflux Disease Trial, Recruiting NCT07093359 Sponsor: University of Oxford Condition: Gastro-oesophageal Reflux Disease
Back to Gord

Phase 3 Gastro-oesophageal Reflux Disease Trial, Recruiting

NCT07093359
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People who are willing and able to give informed consent to participate
  • People with gastro-oesophageal reflux disease (acid reflux) that is not well controlled by medication, or who cannot tolerate the medication, and who are being considered for surgery to treat their reflux
  • People who have confirmed acid reflux symptoms backed up by objective testing, such as an endoscopy showing signs of reflux damage to the oesophagus, or a 24-hour acid monitoring test confirming reflux
  • People who have no hiatal hernia (where part of the stomach pushes up through the diaphragm), or a hiatal hernia that is smaller than 5 cm in size
  • People whose oesophagus (food pipe) has adequate muscle movement and strength, as confirmed by a specialised pre-surgery test called oesophageal manometry

Who may not be able to join:

  • People whose general health makes surgery or general anaesthesia unsafe
  • People with known or suspected allergies to titanium, stainless steel, nickel, or ferrous (iron-based) metals
  • People who have previously had surgery for acid reflux or stomach surgery of any kind
  • People who have previously had brain or spinal surgery, or who have such a procedure planned
  • People whose oesophageal manometry test shows a complete absence of muscle contractions in the lower oesophagus (food pipe)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +44 07584039433

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
6 March 2025
Est. completion
1 February 2029

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Symptomatic GORD and health-related quality of life (HRQL) assessed using the GORD-HRQL questionnaire

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov